Insulin prandial injectable (Albireo Pharma)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameInsulin prandial injectable (Albireo Pharma)
Drug Alias NameVIAjectVIAject 7VIAject 25LinjetaVIAject-7 +[6] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormone
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (NDA/BLA)
Highest Status in ChinaN/A
Originator CompaniesAlbireo Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAlbireo Pharma IncBiodel Inc
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus

Other Information

ATC CodeN/A
Related LinksN/A